Viruses and human cancers: A long road of discovery of molecular paradigms

Clinical Microbiology Reviews

Volumn 27, Issue 3, 2014, Pages 463-481

  White, Martyn K ^a   Pagano, Joseph S ^b   Khalili, Kamel ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ANGIOGENESIS; ARTICLE; CANCER RESEARCH; CARCINOGENICITY; CELL CYCLE; HEPATITIS B; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MERKEL CELL TUMOR; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ESCAPE; VIROLOGY; VIRUS; ANIMAL; COMPLICATION; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; MORTALITY; NEOPLASMS; PHYSIOLOGY; TUMOR VIRUS; VIRUS CELL TRANSFORMATION; VIRUS INFECTION;

ANIMALS; CELL TRANSFORMATION, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; NEOPLASMS; ONCOGENIC VIRUSES; TUMOR VIRUS INFECTIONS;

EID: 84903635751     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00124-13     Document Type: Article

References (190)

1. Harris H. 2005. A long view of fashions in cancer research. Bioessays 27:833-838. http://dx.doi.org/10.1002/bies.20263.
2. Rous P. 1911. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13:397-411. http://dx.doi.org/10.1084 /jem.13.4.397.
3. Stehelin D, Varmus HE, Bishop JM, Vogt PK. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260:170-173. http://dx.doi.org/10.1038/260170a0.
4. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915. http://dx.doi.org/10.1126/science.2144057.
5. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. 1969. Suppression of malignancy by cell fusion. Nature 223:363-368. http://dx.doi.org/10.1038/223363a0.
6. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013.
7. Rubin AL, Yao A, Rubin H. 1990. Relation of spontaneous transformation in cell culture to adaptive growth and clonal heterogeneity. Proc. Natl. Acad. Sci. U. S. A. 87:482-486. http://dx.doi.org/10.1073/pnas.87.1.482.
8. Yao A, Rubin AL, Rubin H. 1990. Progressive state selection of cells in low serum promotes high density growth and neoplastic transformation in NIH 3T3 cells. Cancer Res. 50:5171-5176.
9. Boone CW. 1975. Malignant hemangioendotheliomas produced by subcutaneous inoculation of Balb/3T3 cells attached to glass beads. Science 188:68-70. http://dx.doi.org/10.1126/science.1114343.
10. Boone CW, Takeichi N, Paranjpe M, Gilden R. 1976. Vasoformative sarcomas arising from BALB/3T3 cells attached to solid substrates. Cancer Res. 36:1626-1633.
11. Weiss RA, Vogt PK. 2011. 100 years of Rous sarcoma virus. J. Exp. Med. 208:2351-2355. http://dx.doi.org/10.1084/jem.20112160.
12. Javier RT, Butel JS. 2008. The history of tumor virology. Cancer Res. 68:7693-7706. http://dx.doi.org/10.1158/0008-5472.CAN-08-3301.
13. Shope RE. 1932. A filtrable virus causing a tumor-like condition in rabbits and its relationship to virus myxomatosum. J. Exp. Med. 56:803-822. http://dx.doi.org/10.1084/jem.56.6.803.
14. Bittner JJ. 1936. Some possible effects of nursing on the mammary gland tumor incidence in mice. Science 84:162. http://dx.doi.org/10.1126 /science.84.2172.162-a.
15. Gross L. 1951. "Spontaneous" leukemia developing in C3H mice following inoculation in infancy, with AK-leukemic extracts, or AK-embrvos. Proc. Soc. Exp. Biol. Med. 76:27-32. http://dx.doi.org/10.3181/00379727-76-18379.
16. Stewart SE, Eddy BE, Borgese N. 1958. Neoplasms in mice inoculated with a tumor agent carried in tissue culture. J. Natl. Cancer Inst. 20:1223-1243.
17. Zur Hausen H. 2006. Infections causing human cancer. Wiley, New York, NY.
18. Pagano JS. 1999. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc. Assoc. Am. Physicians 111:573-580. http://dx.doi.org/10.1046/j.1525-1381.1999.t01-1-99220.x.
19. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702-703.
20. Henle G, Henle W, Clifford P, Diehl V, Kafuko GW, Kirya BG, Klein G, Morrow RH, Munube GM, Pike P, Tukei PM, Ziegler JL. 1969. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J. Natl. Cancer Inst. 43:1147-1157.
21. Henle W, Henle G, Zajac BA, Pearson G, Waubke R, Scriba M. 1970. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 169:188-190. http://dx.doi.org/10.1126 /science.169.3941.188.
22. Nonoyama M, Kawai Y, Pagano JS. 1975. Detection of Epstein-Barr virus DNA in human tumors. Bibl. Haematol. 40:577-583.
23. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, Tuffnell PS, Barrell BG. 1984. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207-211. http://dx.doi.org/10.1038/310207a0.
24. Adams A, Lindahl T. 1975. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc. Natl. Acad. Sci. U. S. A. 72:1477-1481. http://dx.doi.org/10.1073/pnas.72.4.1477.
25. Lemon SM, Hutt LM, Shaw JE, Li JL, Pagano JS. 1977. Replication of EBV in epithelial cells during infectious mononucleosis. Nature 268: 268-270. http://dx.doi.org/10.1038/268268a0.
26. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. 1984. Epstein-Barr virus replication in oropharyngeal epithelial cells. N. Engl. J. Med. 310:1225-1230. http://dx.doi.org/10.1056/NEJM198405103101905.
27. Dane DS, Cameron CH, Briggs M. 1970. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet i:695-698.
28. Robinson WS, Clayton DA, Greenman RL. 1974. DNA of a human hepatitis B virus candidate. J. Virol. 14:384-391.
29. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet ii:1129-1133.
30. Wright R. 1990. Viral hepatitis comparative epidemiology. Br. Med. Bull. 46:548-558.
31. zur Hausen H. 1977. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr. Top. Mirobiol. Immunol. 78:1-30.
32. zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW. 1974. Attempts to detect virus-secific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int. J. cancer. Int. J. Cancer 13:650-656.
33. zur Hausen H, Schulte-Holthausen H, Wolf H, Dorries K, Egger H. 1974. Attempts to detect virus-specific DNA in human tumors. II. Nucleic acid hybridizations with complementary RNA of human herpes group viruses. Int. J. cancer. Int. J. Cancer 13:657-664.
34. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. 1984. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 3:1151-1157.
35. Durst M, Gissmann L, Ikenberg H, zur Hausen H. 1983. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. U. S. A. 80:3812-3815. http://dx.doi.org/10.1073/pnas.80.12.3812.
36. Danos O, Katinka M, Yaniv M. 1982. Human papillomavirus 1a complete DNA sequence: a novel type of genome organization among papovaviridae. EMBO J. 1:231-236.
37. Schiffman M, Castle PE. 2003. Human papillomavirus: epidemiology and public health. Arch. Path. Lab. Med. 127:930-934.
38. Yoshida M, Miyoshi I, Hinuma Y. 1982. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. U. S. A. 79:2031-2035. http://dx.doi.org/10.1073/pnas.79.6.2031.
39. Seiki M, Hattori S, Hirayama Y, Yoshida M. 1983. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc. Natl. Acad. Sci. U. S. A. 80:3618-3622. http://dx.doi.org/10.1073/pnas.80.12.3618.
40. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 77:7415-7419. http://dx.doi.org/10.1073 /pnas.77.12.7415.
41. Lairmore MD, Haines R, Anupam R. 2012. Mechanisms of human T-lymphotropic virus type 1 transmission and disease. Curr. Opin. Virol. 2:474-481. http://dx.doi.org/10.1016/j.coviro.2012.06.007.
42. Taylor GP, Matsuoka M. 2005. Natural history of adult T-cell leukemia/ lymphoma and approaches to therapy. Oncogene 24:6047-6057. http: //dx.doi.org/10.1038/sj.onc.1208979.
43. Sonoda S, Li HC, Tajima K. 2011. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci. 102:295-301. http://dx.doi.org/10.1111 /j.1349-7006.2010.01820.x.
44. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. 1975. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 292:767-770. http://dx.doi.org/10.1056/NEJM197504102921502.
45. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362. http://dx.doi.org/10.1126/science.2523562.
46. Gravitz L. 2011. A smouldering public-health crisis. Nature 474:S2-S4. http://dx.doi.org/10.1038/474S2a.
47. Rosen HR. 2011. Clinical practice. Chronic hepatitis C infection. N. Engl. J. Med. 364:2429-2438. http://dx.doi.org/10.1056/NEJMcp1006613.
48. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-29. http://dx.doi.org/10.1053/jhep.2002.36227.
49. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L. 2013. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 58:1215-1224. http: //dx.doi.org/10.1002/hep.26387.
50. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. http://dx.doi.org/10.1126/science.7997879.
51. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDSrelated body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191. http://dx.doi.org/10.1056/NEJM199505043321802.
52. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
53. Corbellino M, Poirel L, Aubin JT, Paulli M, Magrini U, Bestetti G, Galli M, Parravicini C. 1996. The role of human herpesvirus 8 and Epstein-Barr virus in the pathogenesis of giant lymph node hyperplasia (Castleman's disease). Clin. Infect. Dis. 22:1120-1121. http://dx.doi.org /10.1093/clinids/22.6.1120.
54. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U. S. A. 93:14862-14867. http://dx.doi.org/10.1073 /pnas.93.25.14862.
55. Akula SM, Pramod NP, Wang FZ, Chandran B. 2002. Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcomaassociated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 108:407-419. http://dx.doi.org/10.1016/S0092-8674(02)00628-1.
56. Feng H, Taylor JL, Benos PV, Newton R, Waddell K, Lucas SB, Chang Y, Moore PS. 2007. Human transcriptome subtraction by using short sequence tags to search for tumor viruses in conjunctival carcinoma. J. Virol. 81:11332-11340. http://dx.doi.org/10.1128/JVI.00875-07.
57. White MK, Gordon J, Khalili K. 2013. The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog. 9:e1003206. http://dx.doi.org/10.1371/journal.ppat.1003206.
58. White MK, Khalili K. 2004. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology 324:1-16. http://dx.doi.org/10.1016/j.virol.2004.03.025.
59. White MK, Khalili K. 2005. Expression of JC virus regulatory proteins in human cancer: potential mechanisms for tumourigenesis. Eur. J. Cancer. 41:2537-2548. http://dx.doi.org/10.1016/j.ejca.2005.08.019.
60. White MK, Gordon J, Reiss K, Del Valle L, Croul S, Giordano A, Darbinyan A, Khalili K. 2005. Human polyomaviruses and brain tumors. Brain Res. Rev. 50:69-85. http://dx.doi.org/10.1016/j.brainresrev.2005.04.007.
61. Schrama D, Ugurel S, Becker JC. 2012. Merkel cell carcinoma: recent insights and new treatment options. Curr. Opin. Oncol. 24:141-149. http://dx.doi.org/10.1097/CCO.0b013e32834fc9fe.
62. Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, Wong SL. 2007. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 110:1-12. http://dx.doi.org/10.1002/cncr.22765.
63. Duncavage EJ, Zehnbauer BA, Pfeifer JD. 2009. Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod. Pathol. 22:516-521. http://dx.doi.org/10.1038/modpathol.2009.3.
64. Sastre-Garau X, Peter M, Avril MF, Laude H, Couturier J, Rozenberg F, Almeida A, Boitier F, Carlotti A, Couturaud B, Dupin N. 2009. Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J. Pathol. 218:48-56. http: //dx.doi.org/10.1002/path.2532.
65. Mangana J, Dziunycz P, Kerl K, Dummer R, Cozzio A. 2010. Prevalence of Merkel cell polyomavirus among Swiss Merkel cell carcinoma patients. Dermatology 221:184-188. http://dx.doi.org/10.1159/000315067.
66. Martel-Jantin C, Filippone C, Cassar O, Peter M, Tomasic G, Vielh P, Briere J, Petrella T, Aubriot-Lorton MH, Mortier L, Jouvion G, Sastre-Garau X, Robert C, Gessain A. 2012. Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology 426: 134-142. http://dx.doi.org/10.1016/j.virol.2012.01.018.
67. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, Chang Y. 2008. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. U. S. A. 105:16272-16277. http://dx.doi.org/10.1073/pnas.0806526105.
68. Chen T, Hedman L, Mattila PS, Jartti T, Ruuskanen O, Soderlund-Venermo M, Hedman K. 2011. Serological evidence of Merkel cell polyomavirus primary infections in childhood. J. Clin. Virol. 50:125-129. http://dx.doi.org/10.1016/j.jcv.2010.10.015.
69. Kean JM, Rao S, Wang M, Garcea RL. 2009. Seroepidemiology of human polyomaviruses. PLoS Pathog. 5:e1000363. http://dx.doi.org/10.1371/journal.ppat.1000363.
70. Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, Chang Y, Buck CB, Moore PS. 2009. Human Merkel cell polyomavirus infection. II. MCVis a common human infection that can be detected by conformational capsid epitope immunoassays. Int. J. Cancer 125:1250-1256. http://dx.doi.org/10.1002/ijc.24509.
71. Arora R, Chang Y, Moore PS. 2012. MCV and Merkel cell carcinoma: a molecular success story. Curr. Opin. Virol. 2:489-498. http://dx.doi.org /10.1016/j.coviro.2012.05.007.
72. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, Roizman B. 2004. Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 14:453-471. http://dx.doi.org/10.1016/j.semcancer.2004.06.009.
73. Koch R. 1881. Zer Untersuchung van pathogenen Organismen. Mittheil. Kais. Gesundheitsamte 1:1-48.
74. Evans AS, Mueller NE. 1990. Viruses and cancer. Causal associations. Ann. Epidemiol. 1:71-92. http://dx.doi.org/10.1016/1047-2797(90)90020-S.
75. Agelli M, Clegg LX. 2003. Epidemiology of primary Merkel cell carcinoma in the United States. J. Am. Acad. Dermatol. 49:832-841. http://dx.doi.org/10.1016/S0190-9622(03)02108-X.
76. Korzeniewski N, Spardy N, Duensing A, Duensing S. 2011. Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett. 305:113-122. http://dx.doi.org/10.1016/j.canlet.2010.10.013.
77. Hill AB. 1965. The environment and disease: association or causation? Proc. R. Soc. Med. 58:295-300.
78. Bosch X. 1981. Risk factors in human cancer. Rev. Sanidad Hig. Publica 55:477-480.
79. Bility MT, Li F, Cheng L, Su L. 2013. Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models. J. Gastroenterol. Hepatol. 28(Suppl 1):120-124. http://dx.doi.org/10.1111/jgh.12092.
80. Akkina R. 2013. Human immune responses and potential for vaccine assessment in humanized mice. Curr. Opin. Immunol. 25:403-409. http: //dx.doi.org/10.1016/j.coi.2013.03.009.
81. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S. 2005. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl. Cancer Inst. 97:425-432. http://dx.doi.org/10.1093/jnci/dji072.
82. Jensen F, Koprowski H, Ponten JA. 1963. Rapid transformation of human fibroblast cultures by simian virus. Proc. Natl. Acad. Sci. U. S. A. 50:343-348. http://dx.doi.org/10.1073/pnas.50.2.343.
83. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263. http://dx.doi.org/10.1038 /278261a0.
84. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E. 1988. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129. http://dx.doi.org/10.1038 /334124a0.
85. Martinez R, Nakamura KD, Weber MJ. 1982. Identification of phosphotyrosine-containing proteins in untransformed and Rous sarcoma virus-transformed chicken embryo fibroblasts. Mol. Cell. Biol. 2:653-665.
86. Rossomando AJ, Payne DM, Weber MJ, Sturgill TW. 1989. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc. Natl. Acad. Sci. U. S. A. 86:6940-6943. http://dx.doi.org/10.1073/pnas.86.18.6940.
87. Hamid NA, Brown C, Gaston K. 2009. The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol. Life Sci. 66:1700-1717. http://dx.doi.org/10.1007/s00018-009-8631-7.
88. Pett MR, Alazawi WO, Roberts I, Dowen S, Smith DI, Stanley MA, Coleman N. 2004. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 64:1359-1368. http://dx.doi.org/10.1158 /0008-5472.CAN-03-3214.
89. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. 2004. Mechanisms of human papillomavirusinduced oncogenesis. J. Virol. 78:11451-11460. http://dx.doi.org/10.1128/JVI.78.21.11451-11460.2004.
90. Storey A, Banks L. 1993. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene 8:919-924.
91. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. 1993. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 90:5583-5587. http://dx.doi.org/10.1073/pnas.90.12.5583.
92. Song S, Liem A, Miller JA, Lambert PF. 2000. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 267:141-150. http://dx.doi.org/10.1006/viro.1999.0106.
93. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. 1998. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396:84-88. http://dx.doi.org/10.1038/23962.
94. Meyers JM, Spangle JM, Munger K. 2013. The human papillomavirus type 8 E6 protein interferes with NOTCH activation during keratinocyte differentiation. J. Virol. 87:4762-4767. http://dx.doi.org/10.1128/JVI.02527-12.
95. Munger K, Howley PM. 2002. Human papillomavirus immortalization and transformation functions. Virus Res. 89:213-228. http://dx.doi.org /10.1016/S0168-1702(02)00190-9.
96. Vande Pol SB, Klingelhutz AJ. 2013. Papillomavirus E6 oncoproteins. Virology 445:115-137. http://dx.doi.org/10.1016/j.virol.2013.04.026.
97. McLaughlin-Drubin ME, Munger K. 2009. The human papillomavirus E7 oncoprotein. Virology 384:335-344. http://dx.doi.org/10.1016/j.virol.2008.10.006.
98. Beaudenon S, Huibregtse JM. 2008. HPV E6, E6AP and cervical cancer. BMC Biochem. 9(Suppl 1):S4. http://dx.doi.org/10.1186/1471-2091-9-S1-S4.
99. Mantovani F, Banks L. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874-7887. http://dx.doi.org/10.1038/sj.onc.1204869.
100. Felsani A, Mileo AM, Paggi MG. 2006. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25:5277-5285. http://dx.doi.org/10.1038/sj.onc.1209621.
101. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
102. Rawlins DR, Milman G, Hayward SD, Hayward GS. 1985. Sequencespecific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 42:859-868. http://dx.doi.org/10.1016/0092-8674(85)90282-X.
103. Westhoff Smith D, Sugden B. 2013. Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus. Viruses 5:226-240. http://dx.doi.org/10.3390/v5010226.
104. Knutson JC. 1990. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J. Virol. 64:2530-2536.
105. Henkel T, Ling PD, Hayward SD, Peterson MG. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signalbinding protein J. kappa. Science 265:92-95. http://dx.doi.org/10.1126 /science.8016657.
106. Hayward SD, Liu J, Fujimuro M. 2006. Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci. STKE 2006:re4. http://dx.doi.org/10.1126/stke.3352006re4.
107. Bheda A, Yue W, Gullapalli A, Shackelford J, Pagano JS. 2011. PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells. Leuk. Lymphoma 52:1336-1347. http://dx.doi.org/10.3109/10428194.2011.562571.
108. Abbot SD, Rowe M, Cadwallader K, Ricksten A, Gordon J, Wang F, Rymo L, Rickinson AB. 1990. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J. Virol. 64:2126-2134.
109. Wakisaka N, Pagano JS. 2003. Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res. 23:2133-2138.
110. Dawson CW, Port RJ, Young LS. 2012. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin. Cancer Biol. 22:144-153. http: //dx.doi.org/10.1016/j.semcancer.2012.01.004.
111. Pang MF, Lin KW, Peh SC. 2009. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. Cell Mol. Biol. Lett. 14:222-247. http://dx.doi.org/10.2478 /s11658-008-0045-2.
112. Calender A, Cordier M, Billaud M, Lenoir GM. 1990. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int. J. Cancer 46:658-663. http://dx.doi.org/10.1002/ijc.2910460418.
113. Moorthy RK, Thorley-Lawson DA. 1993. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J. Virol. 67:1638-1646.
114. Iwakiri D, Takada K. 2010. Role of EBERs in the pathogenesis of EBV infection. Adv. Cancer Res. 107:119-136. http://dx.doi.org/10.1016 /S0065-230X(10)07004-1.
115. Nanbo A, Takada K. 2002. The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev. Med. Virol. 12:321-326. http://dx.doi.org/10.1002/rmv.363.
116. Marquitz AR, Raab-Traub N. 2012. The role of miRNAs and EBV BARTs in NPC. Semin. Cancer Biol. 22:166-172. http://dx.doi.org/10.1016/j.semcancer.2011.12.001.
117. Radkov SA, Kellam P, Boshoff C. 2000. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6:1121-1127. http://dx.doi.org/10.1038/80459.
118. Wilson JB, Bell JL, Levine AJ. 1996. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15:3117-3126.
119. Drotar ME, Silva S, Barone E, Campbell D, Tsimbouri P, Jurvansu J, Bhatia P, Klein G, Wilson JB. 2003. Epstein-Barr virus nuclear antigen-1 and Myc cooperate in lymphomagenesis. Int. J. Cancer 106:388-395. http://dx.doi.org/10.1002/ijc.11224.
120. Kang MS, Lu H, Yasui T, Sharpe A, Warren H, Cahir-McFarland E, Bronson R, Hung SC, Kieff E. 2005. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc. Natl. Acad. Sci. U. S. A. 102:820-825. http://dx.doi.org/10.1073/pnas.0408774102.
121. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 95:11963-11968. http://dx.doi.org/10.1073/pnas.95.20.11963.
122. Moore PS, Boshoff C, Weiss RA, Chang Y. 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-1744. http://dx.doi.org/10.1126/science.274.5293.1739.
123. Verma SC, Lan K, Robertson E. 2007. Structure and function of latencyassociated nuclear antigen. Curr. Top. Mirobiol. Immunol. 312:101-136.
124. Fujimuro M, Hayward SD. 2003. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J. Virol. 77:8019-8030. http://dx.doi.org/10.1128/JVI.77.14.8019-8030.2003.
125. Friborg J, Jr, Kong W, Hottiger MO, Nabel GJ. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889-894.
126. Mesri EA, Cesarman E, Boshoff C. 2010. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10:707-719. http://dx.doi.org /10.1038/nrc2888.
127. Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Kishishita M, Brady JN, Doniger J, Medveczky P, Rosenthal LJ. 1998. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J. Virol. 72:4980-4988.
128. Xu C, Zhou W, Wang Y, Qiao L. 2014. Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett. 345:216-222. http://dx.doi.org /10.1016/j.canlet.2013.08.035.
129. Guerrieri F, Belloni L, Pediconi N, Levrero M. 2013. Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin. Liver Dis. 33: 147-156. http://dx.doi.org/10.1055/s-0033-1345721.
130. McGivern DR, Lemon SM. 2011. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30: 1969-1983. http://dx.doi.org/10.1038/onc.2010.594.
131. Kew MC. 2011. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 26(Suppl 1):144-152. http://dx.doi.org/10.1111/j.1440-1746.2010.06546.x.
132. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. 1994. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19:810-819. http://dx.doi.org/10.1002/hep.1840190403.
133. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. 1998. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4:1065-1067. http://dx.doi.org/10.1038/2053.
134. Sakamuro D, Furukawa T, Takegami T. 1995. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J. Virol. 69:3893-3896.
135. Zemel R, Gerechet S, Greif H, Bachmatove L, Birk Y, Golan-Goldhirsh A, Kunin M, Berdichevsky Y, Benhar I, Tur-Kaspa R. 2001. Cell transformation induced by hepatitis C virus NS3 serine protease. J. Viral Hepat. 8:96-102. http://dx.doi.org/10.1046/j.1365-2893.2001.00283.x.
136. He QQ, Cheng RX, Sun Y, Feng DY, Chen ZC, Zheng H. 2003. Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 C-terminal deleted protein. World J. Gastroenterol. 9:474-478.
137. Dunsford HA, Sell S, Chisari FV. 1990. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res. 50:3400-3407.
138. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A. 2002. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196:641-653. http: //dx.doi.org/10.1084/jem.20012127.
139. Diao J, Garces R, Richardson CD. 2001. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev. 12:189-205. http://dx.doi.org/10.1016/S1359-6101(00)00034-4.
140. Feitelson MA, Zhu M, Duan LX, London WT. 1993. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109-1117.
141. Banerjee A, Ray RB, Ray R. 2010. Oncogenic potential of hepatitis C virus proteins. Viruses 2:2108-2133. http://dx.doi.org/10.3390 /v2092108.
142. Ishido S, Hotta H. 1998. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett. 438:258-262. http://dx.doi.org/10.1016/S0014-5793(98)01312-X.
143. Saito M. 2014. Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis. J. Neurovirol. 20:164-174. http://dx.doi.org/10.1007/s13365-013-0192-8.
144. Currer R, Van Duyne R, Jaworski E, Guendel I, Sampey G, Das R, Narayanan A, Kashanchi F. 2012. HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front. Microbiol. 3:406. http://dx.doi.org/10.3389/fmicb.2012.00406.
145. Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G, Jay G. 1987. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science 237:1324-1329. http://dx.doi.org/10.1126/science.2888190.
146. Baranger AM, Palmer CR, Hamm MK, Giebler HA, Brauweiler A, Nyborg JK, Schepartz A. 1995. Mechanism of DNA-binding enhancement by the human T-cell leukaemia virus transactivator Tax. Nature 376:606-608. http://dx.doi.org/10.1038/376606a0.
147. Chlichlia K, Khazaie K. 2010. HTLV-1 Tax: linking transformation, DNAdamage and apoptotic T-cell death. Chem. Biol. Interact. 188:359-365. http://dx.doi.org/10.1016/j.cbi.2010.06.005.
148. Seiki M, Eddy R, Shows TB, Yoshida M. 1984. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 309:640-642. http://dx.doi.org/10.1038/309640a0.
149. Bai XT, Nicot C. 2012. Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis. Front. Microbiol. 3:400. http://dx.doi.org/10.3389/fmicb.2012.00400.
150. Nicot C, Mulloy JC, Ferrari MG, Johnson JM, Fu K, Fukumoto R, Trovato R, Fullen J, Leonard WJ, Franchini G. 2001. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 98:823-829. http://dx.doi.org/10.1182/blood.V98.3.823.
151. Awasthi S, Sharma A, Wong K, Zhang J, Matlock EF, Rogers L, Motloch P, Takemoto S, Taguchi H, Cole MD, Luscher B, Dittrich O, Tagami H, Nakatani Y, McGee M, Girard AM, Gaughan L, Robson CN, Monnat RJ, Jr, Harrod R. 2005. A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions. Mol. Cell. Biol. 25:6178-6198. http: //dx.doi.org/10.1128/MCB.25.14.6178-6198.2005.
152. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore PS, Becker JC. 2010. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J. Virol. 84: 7064-7072. http://dx.doi.org/10.1128/JVI.02400-09.
153. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, Henzel K, Hauser S, Elling R, Brocker EB, Gaubatz S, Becker JC, Schrama D. 2012. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int. J. cancer. Int. J. Cancer 130: 847-856. http://dx.doi.org/10.1002/ijc.26076.
154. Liu X, Hein J, Richardson SC, Basse PH, Toptan T, Moore PS, Gjoerup OV, Chang Y. 2011. Merkel cell polyomavirus large T antigen disrupts lysosome clustering by translocating human Vam6p from the cytoplasm to the nucleus. J. Biol. Chem. 286:17079-17090. http://dx.doi.org/10.1074/jbc.M110.192856.
155. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. 2011. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J. Clin. Invest. 121:3623-3634. http://dx.doi.org/10.1172/JCI46323.
156. Kwun HJ, Shuda M, Feng H, Camacho CJ, Moore PS, Chang Y. 2013. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe 14:125-135. http://dx.doi.org/10.1016/j.chom.2013.06.008.
157. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ. 2008. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 18:397-408. http://dx.doi.org/10.1016/j.semcancer.2008.10.008.
158. Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, Wiertz EJ, Rowe M. 2009. The Epstein-Barr virus G-proteincoupled receptor contributes to immune evasion by targetingMHCclass I molecules for degradation. PLoS Pathog. 5:e1000255. http://dx.doi.org /10.1371/journal.ppat.1000255.
159. Middeldorp JM, Pegtel DM. 2008. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin. Cancer Biol. 18:388-396. http://dx.doi.org/10.1016/j.semcancer.2008.10.004.
160. Chen Y, Cheng M, Tian Z. 2006. Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell. Mol. Immunol. 3:373-378.
161. Grabowska AK, Riemer AB. 2012. The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol. J. 6:249-256. http://dx.doi.org/10.2174 /1874357901206010249.
162. Georgopoulos NT, Proffitt JL, Blair GE. 2000. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 19:4930-4935. http://dx.doi.org/10.1038/sj.onc.1203860.
163. Ashrafi GH, Brown DR, Fife KH, Campo MS. 2006. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res. 120:208-211. http://dx.doi.org/10.1016/j.virusres.2006.02.005.
164. Geiger TR, Martin JM. 2006. The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells. J. Virol. 80:11638-11650. http://dx.doi.org/10.1128/JVI.01570-06.
165. Zhang L, Pagano JS. 1997. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol. Cell. Biol. 17:5748-5757.
166. Ning S, Pagano JS, Barber GN. 2011. IRF7: activation, regulation, modification and function. Genes Immun. 12:399-414. http://dx.doi.org/10.1038/gene.2011.21.
167. Guo P. 2013. Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress. Scand. J. Immunol. 78:230-237. http://dx.doi.org/10.1111/sji.12086.
168. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M. 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178:3186-3197.
169. Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, Manet E, Tommasino M, Sylla BS, Hasan UA. 2010. EBV latent membrane protein 1 is a negative regulator of TLR9. J. Immunol. 185:6439-6447. http://dx.doi.org/10.4049/jimmunol.0903459.
170. Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, Zannetti C, Hasan U, Chang Y, Moore PS, Accardi R, Tommasino M. 2013. The T antigen locus of merkel cell polyomavirus downregulates human Tolllike receptor 9 expression. J. Virol. 87:13009-13019. http://dx.doi.org/10.1128/JVI.01786-13.
171. Ronco LV, Karpova AY, Vidal M, Howley PM. 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:2061-2072. http://dx.doi.org/10.1101/gad.12.13.2061.
172. Li K, Lemon SM. 2013. Innate immune responses in hepatitis C virus infection. Semin. Immunopathol. 35:53-72. http://dx.doi.org/10.1007 /s00281-012-0332-x.
173. Arzumanyan A, Reis HM, Feitelson MA. 2013. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 13:123-135. http://dx.doi.org/10.1038/nrc3449.
174. Sathish N, Yuan Y. 2011. Evasion and subversion of interferonmediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: an overview. J. Virol. 85:10934-10944. http://dx.doi.org/10.1128 /JVI.00687-11.
175. Lee HR, Brulois K, Wong L, Jung JU. 2012. Modulation of immune system by Kaposi's sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front. Microbiol. 3:44. http://dx.doi.org/10.3389 /fmicb.2012.00044.
176. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. 2000. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcomaassociated herpesvirus K3 and K5 proteins. J. Virol. 74:5300-5309. http://dx.doi.org/10.1128/JVI.74.11.5300-5309.2000.
177. Stevenson PG, Efstathiou S, Doherty PC, Lehner PJ. 2000. Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses. Proc. Natl. Acad. Sci. U. S. A. 97:8455-8460. http://dx.doi.org/10.1073/pnas.150240097.
178. Belanger C, Gravel A, Tomoiu A, Janelle ME, Gosselin J, Tremblay MJ, Flamand L. 2001. Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J. Hum. Virol. 4:62-73.
179. Neurath AR, Strick N. 1990. Antigenic mimicry of an immunoglobulin A epitope by a hepatitis B virus cell attachment site. Virology 178:631-634. http://dx.doi.org/10.1016/0042-6822(90)90368-2.
180. Locarnini S, Zoulim F. 2010. Molecular genetics of HBV infection. Antiviral Ther. 15(Suppl 3):3-14. http://dx.doi.org/10.3851/IMP1619.
181. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229. http://dx.doi.org/10.1038/nri1573.
182. Brunetto MR, Rodriguez UA, Bonino F. 1999. Hepatitis B virus mutants. Intervirology 42:69-80. http://dx.doi.org/10.1159/000024968.
183. Doorbar J. 2013. Latent papillomavirus infections and their regulation. Curr. Opin. Virol. 3:416-421. http://dx.doi.org/10.1016/j.coviro.2013.06.003.
184. Gravitt PE. 2012. Evidence and impact of human papillomavirus latency. Open Virol. J. 6:198-203. http://dx.doi.org/10.2174/1874357901206010198.
185. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM, Nghiem P. 2011. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin. Cancer Res. 17:6671-6680. http://dx.doi.org/10.1158/1078-0432.CCR-11-1513.
186. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. 2008. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann. Neurol. 64:379-387. http://dx.doi.org/10.1002/ana.21443.
187. Soderberg-Naucler C, Johnsen JI. 2012. Cytomegalovirus infection in brain tumors: a potential new target for therapy? Oncoimmunology 1:739-740. http://dx.doi.org/10.4161/onci.19441.
188. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62:3347-3350.
189. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, Khan Z, Sveinbjornsson B, FuskevAg OM, Segerstrom L, Nordenskjold M, Siesjo P, Kogner P, Johnsen JI, Soderberg-Naucler C. 2011. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J. Clin. Invest. 121:4043-4055. http://dx.doi.org/10.1172/JCI57147.
190. Soroceanu L, Cobbs CS. 2011. Is HCMV a tumor promoter? Virus Res. 157:193-203. http://dx.doi.org/10.1016/j.virusres.2010.10.026.